GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery | MicrobiomeTrials
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2009-03-31Est. Completion: 2013-01-22
Enrollment target: 55 participants
Locations
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Orlando Health Cancer Institute, Orlando, Florida, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Other microbiome trials you might be interested in